Healthcare / BiotechnologyNasdaqCM
$1.17
-0.02 (-1.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-8.4M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-113.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-4.5M · FCF $-6.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-4.5M | $-4.5M | $-9.9M | $-14.9M | $-12.4M | $-5.0M | $-4.4M |
| EBITDA | $-4.4M | $-4.4M | $-9.9M | $-14.8M | $-12.3M | — | — |
| EPS | -11.32 | -11.32 | -132.33 | -228.90 | -189.00 | — | — |
| Balance Sheet | |||||||
| Debt/Equity | — | — | -0.12 | — | — | — | — |
| Current Ratio | 1.99 | 1.99 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-6.9M | $-6.9M | $-8.4M | $-8.9M | $-6.7M | — | — |
| Returns | |||||||
| ROE | -113.8% | -113.8% | 383.5% | -488.5% | -92.6% | -250.7% | -536.7% |
| Valuation | |||||||
| P/B | 0.13 | 0.13 | — | 14.81 | 6.60 | — | — |
| Growth & Yield | |||||||
| EPS Growth | 91.4% | 91.4% | 42.2% | -21.1% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-132.33 → -11.32
Residual
-69.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.